API | evinacumab

evinacumab (EVKEEZA) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA

AACT ChEMBL

Active Ingredient History

NOW

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
evinacumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Angiopoietin-related protein 3 (Homo sapiens) ^UniProt
- Angiopoietin-related protein 3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

evinacumab | regn1500 | regn-1500

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Homozygous Familial Hypercholesterolemia (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Healthy Volunteers (Phase 1)

Homozygous Familial Hypercholesterolemia (Phase 4)

Hypercholesterolemia (Phase 2)

Hypertriglyceridemia (Phase 2)

Metabolic Diseases (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue